抗肿瘤药物引发心脏和血管毒性 - 最新进展。
Antineoplastic drugs inducing cardiac and vascular toxicity - An update.
发表日期：2023 Sep 05
作者：
Serena Barachini, Sandra Ghelardoni, Zoltán V Varga, Radwa A Mehanna, Maria Magdalena Montt-Guevara, Péter Ferdinandy, Rosalinda Madonna
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS
摘要：
随着抗肿瘤治疗方案的进步以及新型靶向治疗和免疫治疗的发展，癌症预后有所改善，患者的生存率也呈增长趋势。然而，由于抗肿瘤药物增加了心血管不良反应，癌症幸存者的发病率也在同步增加。抗肿瘤疗法常见的心血管并发症包括心律失常、心肌缺血、左室功能障碍导致心力衰竭，以及动脉高压、血栓栓塞事件和动脉粥样硬化等血管并发症。这些毒副作用是由于这些药物不仅靶向癌细胞，还会影响心血管系统内的正常细胞。本文将回顾抗肿瘤药物引起的心血管毒性的临床特征和主要机制，包括氧化应激、炎症、免疫血栓形成和生长因子诱导的信号通路。版权所有 © 2023. Elsevier Inc.发表。
With the improvement in cancer prognosis due to advances in antitumor therapeutic protocols and new targeted and immunotherapies, we are witnessing a growing increase in survival, however, at the same timeincrease in morbidity among cancer survivors as a consequences of the increased cardiovascular adverse effects of antineoplastic drugs. Common cardiovascular complications of antineoplastic therapies may include cardiac complications such as arrhythmias, myocardial ischemia, left ventricular dysfunction culminating in heart failure as well as vascular complications including arterial hypertension, thromboembolic events, and accelerated atherosclerosis. The toxicity results from the fact that these drugs not only target cancer cells but also affect normal cells within the cardiovascular system. In this article, we review the clinical features and main mechanisms implicated in antineoplastic drug-induced cardiovascular toxicity, including oxidative stress, inflammation, immunothrombosis and growth factors-induced signaling pathways.Copyright © 2023. Published by Elsevier Inc.